WindMIL Therapeutics Announces Data on Marrow-Infiltrating Lymphocytes Selected for Poster Presentation at 60th American Society of Hematology Annual Meeting
26 nov. 2018 16h30 HE
|
WindMIL Therapeutics
BALTIMORE, Nov. 26, 2018 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, today announced that...